Securities code: 688185 securities abbreviation: Cansino Biologics Inc(688185) Announcement No.: 2022-013 Cansino Biologics Inc(688185) Jinyu Bio-Technology Co.Ltd(600201) company
Announcement of 2021 annual performance express
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear legal responsibility for the authenticity, accuracy and integrity of its contents according to law.
The main financial data of 2021 contained in this announcement are preliminary accounting data, which have not been audited by an accounting firm. The specific data are subject to the company’s 2021 annual report, and investors are reminded of investment risks.
1、 Main financial data and indicators in 2021
Unit: 10000 yuan
Increase / decrease range of the project in the same period of last year in the reporting period (%)
Total operating income 429970.23 2489.04 17174.54
Operating profit 194079.47 – 39781.90 not applicable
Total profit 193678.69 -39663.82 not applicable
191439.00 -39663.82 attributable to the owner of the parent company is not applicable to the net profit
Attributable to the owner of the parent company
Net profit after deducting non recurring profit and loss 179703.77 -51133.21 inapplicable profit
Basic earnings per share (yuan) 7.74 -1.72 not applicable
The weighted average return on net assets of 27.21% – 13.49% is not applicable
Increase / decrease range at the end of the reporting period (%)
Total assets 1187418.70 674807.37 75.96
Owner’s equity attributable to the parent company: 799504.62 607085.42 31.70
Share capital (10000 shares) 24744.99-
32.31 24.53 31.72 net assets per share attributable to the owner of the parent company (yuan)
Note: 1. The beginning amount of this report is the same as the end of the previous year legally disclosed.
2. The above financial data and indicators are filled in with the data in the consolidated statements, which have not been audited. The final results are subject to the company’s 2021 annual report.
2、 Description of operating performance and financial status
(I) operating conditions, financial conditions and main factors affecting operating performance during the reporting period
During the reporting period, the company achieved an operating revenue of 4299.7023 million yuan, a year-on-year increase of 17174.54%; The net profit attributable to the owners of the parent company was 1914.39 million yuan; The net profit attributable to the owner of the parent company after deducting non recurring profits and losses was 1797037700 yuan, which turned losses into profits. At the end of the reporting period, the total assets of the company were 11874187000 yuan, a year-on-year increase of 75.96%; The owner’s equity attributable to the parent company was 7995.0462 million yuan, a year-on-year increase of 31.70%.
(II) the main reasons for the increase or decrease of relevant items in the above table is more than 30%
1. During the reporting period, the company’s total operating income, operating profit, total profit, net profit attributable to the owner of the parent company, net profit excluding non recurring profits and losses attributable to the owner of the parent company, basic earnings per share and weighted average return on net assets changed significantly, Mainly with the recombinant New Coronavirus vaccine (type 5 adenovirus vector) (trade name: Ke Wei Sha) ®） It has obtained conditional listing approval and emergency use authorization from many countries at home and abroad. The commercialization of the product has a positive impact on the company’s total operating revenue and relevant profit indicators.
2. At the end of the reporting period, the total assets of the company increased by 75.96% year-on-year, mainly due to the increase of monetary capital, accounts receivable, inventory and other current assets caused by the growth of the company’s revenue scale during the reporting period, as well as the increase of prepayments; And in order to expand the production scale, fixed assets, construction in progress and other non current assets increased.
3. At the end of the reporting period, the company’s owner’s equity attributable to the parent company increased by 31.70% year-on-year, and the net assets per share attributable to the owner of the parent company increased by 31.72% year-on-year, mainly due to the increase in undistributed profits caused by the company’s turning losses into profits and the increase in net profits from operations.
3、 Risk tips
The main financial data of 2021 contained in this announcement are preliminary accounting data, which have not been audited by an accounting firm. The specific data shall be subject to the company’s 2021 annual report. Please pay attention to the investment risks.
It is hereby announced.
Board of directors of Cansino Biologics Inc(688185) Jinyu Bio-Technology Co.Ltd(600201) February 26, 2022
